VolitionRx (NYSE:VNRX) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a research report issued on Saturday. The brokerage set a “sell” rating on the stock.

Other research analysts also recently issued research reports about the stock. Benchmark reissued a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd. D. Boral Capital reissued a “buy” rating and issued a $5.00 price objective on shares of VolitionRx in a research report on Tuesday.

VolitionRx Stock Down 7.4 %

NYSE VNRX opened at $0.57 on Friday. VolitionRx has a fifty-two week low of $0.43 and a fifty-two week high of $1.23. The business has a fifty day moving average of $0.68 and a 200-day moving average of $0.67. The stock has a market cap of $52.36 million, a price-to-earnings ratio of -1.57 and a beta of 1.17.

Insider Activity

In related news, CEO Cameron John Reynolds bought 139,811 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The shares were acquired at an average cost of $0.57 per share, with a total value of $79,692.27. Following the completion of the transaction, the chief executive officer now owns 2,117,404 shares of the company’s stock, valued at approximately $1,206,920.28. The trade was a 7.07 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Guy Archibald Innes bought 174,764 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was bought at an average price of $0.57 per share, with a total value of $99,615.48. Following the completion of the acquisition, the director now owns 617,085 shares of the company’s stock, valued at $351,738.45. This trade represents a 39.51 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 358,266 shares of company stock valued at $204,212 over the last quarter. Company insiders own 12.80% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in VolitionRx stock. Geode Capital Management LLC raised its holdings in shares of VolitionRx Limited (NYSE:VNRX) by 15.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 730,448 shares of the company’s stock after buying an additional 95,900 shares during the period. Geode Capital Management LLC owned about 0.79% of VolitionRx worth $439,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.